Compare Inovio Pharmaceuticals Inc (INO) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs DENTSPLY SIRONA Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.13 (market cap $112.19M), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: DENTSPLY SIRONA Inc is far larger — about 15.4× Inovio Pharmaceuticals Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| INO | XRAY | |
|---|---|---|
Market Cap | $112.19M | $1.73B |
Volume | 3,201,278 | 6,198,582 |
Sector | Health | Health |
52-Week High | $2.65 | $14.68 |
52-Week Low | $0.66 | $8.52 |
Typical Hold Time | 43 Days | 72 Days |
Enterprise Value | $83.51M | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Dentsply Sirona (XRAY) trades at $8.73, near its 52-week low, with a bearish technical signal and negative profitability metrics. The company reported a Q2 2026 earnings beat but faces declining revenue and negative net income margins. Recent news highlights institutional stake increases and ongoing restructuring efforts amid a challenging dental market environment.
The outlook remains cautious due to persistent margin pressure and sales declines, though the consensus price target of $13.40 suggests potential upside. Key risks include competitive pressures and execution of the turnaround plan, while institutional buying indicates some long-term confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
